[ad_1]
Malden, Massachusetts., December 1, 2021 /PRNewswire-PRNewswire/ – Spine surgeons and patients have a growing demand for artificial disc replacement to replace spinal fusion to treat lumbar disc degeneration.Therefore, AxioMed viscoelastic lumbar and cervical artificial disc replacement is widely anticipated America As a major advancement in artificial disc replacement technology internationally. Competitive ball and socket designs on the market have been plagued by ectopic bone formation and microscopic wear debris, which can lead to osteolysis, as we have seen in hip and knee replacements in the early years.
Leaders in the spinal fusion industry are increasingly investing in pedicle screws and intervertebral fusion cages for spinal fusion to increase direct revenue, thereby pushing up the overall cost of patient care, while there is little improvement in patient treatment results . More data now show that disc replacement is better than spinal fusion in the treatment of disc disease. However, since the failure of Charite lumbar disc replacement, the focus has been on cervical artificial disc replacement due to the insurance reimbursement pressure of lumbar artificial disc replacement. Today, almost all major insurance companies are underwriting artificial disc replacement, but most companies do not invest in lumbar disc replacement, but rely on mergers and acquisitions. AxioMed is the only viscoelastic lumbar disc substitute that has completed the IDE clinical study in the United States, and it will be one of the three lumbar discs expected to be on the market in 2022. …
The full story can be found on Benzinga.com
[ad_2]
Source link
